BARCELONA, February 19, 2024 Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its full-year 2023 financial results.
Almirall, S.A. (OTCMKTS:LBTSF – Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 108,000 shares, a growth of 12.5% from the December 31st total of 96,000 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. […]
Almirall, S.A. (OTCMKTS:LBTSF – Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 77,300 shares, a growth of 24.3% from the November 30th total of 62,200 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio […]
BARCELONA, Spain & NIEL, Belgium, December 12, 2023 Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.